Non-peptide
Rapamycin
Also known as
Sirolimus · Rapamune · Rapamune (brand) · Rapamune / sirolimus generics · AY-22989 (historical research designation) · mTOR inhibitor (class discussion) · Rapalog parent compound · Rapa (forum shorthand) · Sirolimus oral tablet / solution · Compounded rapamycin (clinic/telehealth form)
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Sirolimus | Rapamycin is the prescription mTOR inhibitor sirolimus; Rapamune is a brand. Longevity discussion usually concerns swallowed tablets or compounded capsules. |
|---|---|
| Healthy-aging theory | Users frame intermittent mTOR inhibition as encouraging cellular cleanup between growth signals. This theory and weekly experiments have not established human life extension. |
| What mTOR means | mTOR helps cells respond to nutrients and grow. Users hope that interrupting that signal encourages cellular maintenance; that theory is different from showing that people live longer. |
Notes
Rapamycin, also called sirolimus, is a prescription mTOR inhibitor discussed for healthy aging. Community reports range from fewer aches and better stamina to no change, mouth sores or fatigue. Weekly experiments have not established human life extension.
Sirolimus and rapamycin are the same drug. Rapamune is a brand. Longevity talk concerns swallowed tablets or compounded capsules. Oral solution, topical use and other rapalogs have separate contexts. Rapamune U.S. prescribing information (Official context · Accessed 2026-09-30)
The idea is less growth signaling, more maintenance. mTOR helps cells respond to nutrients and grow. Forum users frame intermittent inhibition as encouraging cellular cleanup while allowing recovery between doses; that theory does not establish a rejuvenation result. Rapamycin Cycling (Time Off) - Who Is Right? (Community discussion · Accessed 2026-09-30) · Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results (Official context · Accessed 2026-09-30)
A longer healthy life remains the hope. Kauppi explicitly treats lifespan benefit as uncertain. Feeling younger or changing an age calculator cannot show that someone will live longer. Krister Kauppi: My rapamycin journey notes (Personal report · Accessed 2026-09-30) · 6 month Rapamycin Results (Personal report · Accessed 2026-09-30)
Source context — Rapamune U.S. prescribing information: Approved clinical-use populations differ from healthy intermittent longevity users; labeled frequencies cannot be transferred. Preparation instructions not reproduced.
Source context — Rapamycin Cycling (Time Off) - Who Is Right?: Opening describes conflicting secondhand calendars; typo in one off-period prevents a reliable number. Mechanistic extrapolation does not prove an optimal cycle.
Source context — Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results: 48-week selected cohort, secondary subgroup findings, no lifespan endpoint. Authors disclose AgelessRx employment/shareholding. Supplements not inspected.
Source context — Krister Kauppi: My rapamycin journey notes: One named self-experimenter with exercise, diet and fasting changes; linked X bodies not inspected. Later thread pages not reviewed.
Source context — 6 month Rapamycin Results: Author has type 2 diabetes, metformin co-use and diet/exercise changes. Linked lab image not inspected; calculator counterfactual is not measured rejuvenation.
What people notice
| Aches, stamina and recovery | Some describe less stiffness, more energy or improved activity capacity; others report fatigue. A recent Long COVID responder still had substantial symptoms. |
|---|---|
| No felt benefit | One 8 mg weekly user reported no effects; another had skin irritation without psychological benefit after a month. Feeling younger or changing an age calculator does not prove longer life. |
Notes
Fewer aches and better recovery are reported. The feel thread includes energy and less stiffness, alongside tiredness or no change. How does Rapamycin make you feel? (Community discussion · Accessed 2026-09-30)
Fatigue communities report both improvement and setbacks. A September 2026 Long COVID account described better activity capacity after four months but substantial remaining symptoms. Other respondents reported uncertainty after 3.5 weeks or no neurological benefit. Rapamycin & Baricinitib (Community discussion · Accessed 2026-09-30)
No noticeable benefit is also reported. Phil_Van_Treuren reports no effects at 8 mg weekly; another contributor has skin irritation without psychological benefit after a month. How does Rapamycin make you feel? (Community discussion · Accessed 2026-09-30)
A longer healthy life remains the hope. Kauppi explicitly treats lifespan benefit as uncertain. Feeling younger or changing an age calculator cannot show that someone will live longer. Krister Kauppi: My rapamycin journey notes (Personal report · Accessed 2026-09-30) · 6 month Rapamycin Results (Personal report · Accessed 2026-09-30)
Source context — How does Rapamycin make you feel?: Self-selected reports; interacting grapefruit and supplement co-use confound some accounts. No causal outcomes or prevalence.
Source context — Rapamycin & Baricinitib: Self-selected Long COVID sample; multiple medicines. Lack of ulcers/infections cannot establish absence of immunosuppression. No combination safety established.
Source context — Krister Kauppi: My rapamycin journey notes: One named self-experimenter with exercise, diet and fasting changes; linked X bodies not inspected. Later thread pages not reviewed.
Source context — 6 month Rapamycin Results: Author has type 2 diabetes, metformin co-use and diet/exercise changes. Linked lab image not inspected; calculator counterfactual is not measured rejuvenation.
Doses people talk about
| 5–7 mg once weekly | This oral-tablet discussion band centers on 6 mg per administration. It is off-label talk, not a validated longevity amount. |
|---|---|
| Lower and higher weekly reports | Saved accounts include 2–3 mg or clinic-style 2–4 mg beginnings and separate 8–10 mg weekly reports. These amounts come from different users and do not form a dose progression. |
| Longer intervals | Talk includes 10–15 mg every other week. Individual reports list 8 mg every nine days, form unstated, or 12 mg compounded capsules every 14 days; these are per-dose totals. |
| Minority daily patterns | Older notes include 1 mg every other day and 1–3 mg daily. One autoimmune-symptom account describes 1 mg daily for three weeks then one week off, a different purpose and exposure. |
Notes
5–7 mg oral tablets once weekly is an established discussion band. The original generic-tablet record centers on 6 mg per administration, including a cited 2023 self-report survey. This describes off-label talk, not a validated longevity amount.
Lower and higher weekly amounts remain separate. Original accounts include 2–3 mg and clinic-style 2–4 mg weekly beginnings, alongside separate 8–10 mg weekly reports. The recorded 3–10 mg range combines different users' amounts; it does not describe one person's progression.
Longer intervals include 10–15 mg every other week. Older notes also contain every-10–14-day schedules. A fresh ME/CFS commenter reports 8 mg every 9 days, form unstated; another reports 12 mg compounded capsules every 14 days. These are per-dose totals. Rapamycin Experiences (Personal report · Accessed 2026-09-30) · 6mg weekly - Planning to change to 6mg fortnightly. Seeking advice (Personal report · Accessed 2026-09-30)
Daily and unusual pulses are minority patterns. Older notes include 1 mg every other day, 1–3 mg daily and teens–20+ mg intermittent outliers. A fatigue-thread user reports 1 mg daily for three weeks, then one week off, for autoimmune symptoms. Different purposes and exposure matter. Fatigue - Side Effect (Community discussion · Accessed 2026-09-30)
Source context — Rapamycin Experiences: Anonymous ME/CFS report; product/form and length of retained benefit not supplied. Not healthy-aging or lifespan evidence.
Source context — 6mg weekly - Planning to change to 6mg fortnightly. Seeking advice: Anonymous account; schedule change is proposed, not its demonstrated outcome. Exercise measures are self-reported.
Source context — Fatigue - Side Effect: Different autoimmune and transplant contexts cannot establish a healthy longevity regimen. Symptom-based half-life guesses are not measurements.
Half-life, onset & duration
| Felt onset | Same-day energy or tiredness is reported. Other accounts place less pain at week two or better sleep after 3–6 months; none gives a universal waiting period. |
|---|---|
| Felt duration | Fatigue can last a few hours or into the next day. One adverse account describes increased fatigue for about two months after stopping; other persistence reports lack a duration. |
| Half-life | About 60–63 hours is repeated label-derived shorthand. The measured label value is 62 ± 16 hours during repeated dosing in stable renal-transplant patients, separate from healthy weekly users. |
Notes
Same-day sensations can be energy or tiredness. Both occur in the feel thread. Phoenix Rising’s Mary reports disrupted sleep after nighttime tablets; her corrected initial amount is 2 mg weekly. How does Rapamycin make you feel? (Community discussion · Accessed 2026-09-30) · Started rapamycin 7/14/2026 - UPDATE: 9/29/26 (Personal report · Accessed 2026-09-30)
Two weeks and several months are different reports. Presentlava reports less pain and better strength after week 2. RapAdmin recalls improved sleep after 3–6 months. Neither is a universal waiting period. Rapamycin Experiences (Personal report · Accessed 2026-09-30) · How does Rapamycin make you feel? (Community discussion · Accessed 2026-09-30)
Fatigue can last hours or into the next day. Arhu describes a few hours; scta123 reports afternoon-through-next-day tiredness after morning weekly use. How does Rapamycin make you feel? (Community discussion · Accessed 2026-09-30) · Fatigue - Side Effect (Community discussion · Accessed 2026-09-30)
Changes after stopping have no consistent time limit. Presentlava says first-course benefits persisted, without a duration. A separate adverse Long COVID account reports increased fatigue lasting about two months after stopping. Rapamycin Experiences (Personal report · Accessed 2026-09-30) · Bad outcome from rapamycin (Personal report · Accessed 2026-09-30)
About 60–63 hours is repeated label-derived shorthand. A fatigue-thread reply repeats 63 hours, without personal measurement. Original “10–14 days to clear” lore extrapolates half-lives rather than establishing an exact washout. Fatigue - Side Effect (Community discussion · Accessed 2026-09-30)
The label’s measured half-life is 62 ± 16 hours. Repeated-dose, stable renal-transplant blood elimination: not a measured healthy weekly-user clock. Rapamune U.S. prescribing information (Official context · Accessed 2026-09-30)
Source context — How does Rapamycin make you feel?: Self-selected reports; interacting grapefruit and supplement co-use confound some accounts. No causal outcomes or prevalence.
Source context — Started rapamycin 7/14/2026 - UPDATE: 9/29/26: Page 2 failed access, so title does not establish inspection of September 29 update. Early dose typo corrected by author; other supplements and illness confound changes.
Source context — Rapamycin Experiences: Anonymous ME/CFS report; product/form and length of retained benefit not supplied. Not healthy-aging or lifespan evidence.
Source context — Fatigue - Side Effect: Different autoimmune and transplant contexts cannot establish a healthy longevity regimen. Symptom-based half-life guesses are not measurements.
Source context — Bad outcome from rapamycin: Long COVID account; narrative and TL;DR disagree on the number of 1 mg weeks. Drug causation and immune mechanism are not established.
Source context — Rapamune U.S. prescribing information: Approved clinical-use populations differ from healthy intermittent longevity users; labeled frequencies cannot be transferred. Preparation instructions not reproduced.
Cycles people discuss
| Continuation or holidays | Patterns include ongoing weekly use, 4–8-week pauses every 3–6 months and a competing five-weeks-on/eight-off claim. No superior calendar is demonstrated. |
|---|---|
| Symptom courses and interruptions | Some describe six-week courses; illness, ulcers, healing concerns or changed blood tests interrupt others. No universal off-period or surgical-hold deadline emerges. |
Notes
Weekly continuation and deliberate holidays both appear. Kauppi planned ongoing weekly use. Original clinic/forum lore discusses 4–8-week pauses every 3–6 months; a cycling thread repeats a competing 5-weeks-on/8-weeks-off claim. No superior calendar is demonstrated. Krister Kauppi: My rapamycin journey notes (Personal report · Accessed 2026-09-30) · Rapamycin Cycling (Time Off) - Who Is Right? (Community discussion · Accessed 2026-09-30)
Some symptom-focused users describe six-week courses. Presentlava describes a second course planned for at least six weeks. That differs from indefinite longevity experimentation and gives no agreed off-period. Rapamycin Experiences (Personal report · Accessed 2026-09-30)
Illness, ulcers and healing interrupt schedules. Kauppi records a one-week ulcer pause and travel/illness breaks. Older notes also describe pauses, lower amounts or longer intervals after lipid/glucose/CBC changes; surgical holds vary rather than following one universal deadline. Krister Kauppi: My rapamycin journey notes (Personal report · Accessed 2026-09-30)
Source context — Krister Kauppi: My rapamycin journey notes: One named self-experimenter with exercise, diet and fasting changes; linked X bodies not inspected. Later thread pages not reviewed.
Source context — Rapamycin Cycling (Time Off) - Who Is Right?: Opening describes conflicting secondhand calendars; typo in one off-period prevents a reliable number. Mechanistic extrapolation does not prove an optimal cycle.
Source context — Rapamycin Experiences: Anonymous ME/CFS report; product/form and length of retained benefit not supplied. Not healthy-aging or lifespan evidence.
Stacks
| Metabolic and longevity drugs | Metformin/acarbose, NMN/NR, spermidine, LDN and lipid/glucose medicines appear. Their amounts are separate; animal combination stories do not validate human stacks. |
|---|---|
| Separate pulses | Some protocols put fisetin or dasatinib–quercetin pulses on a different calendar from weekly rapamycin. This is community practice, without established combination benefit. |
Notes
Stacks make credit and blame harder to assign. Original discussion includes metformin/acarbose, NMN/NR, spermidine, separate fisetin or dasatinib–quercetin pulses, LDN and lipid/glucose medicines. These are separate agents, without a fixed rapamycin ratio; animal combo stories do not validate human stacks.
Metformin: Most-named dual stack — AMPK + mTOR nutrient-sensing; also discussed as metabolic offset for rapa-related glucose/TG drift. Doses are separate drugs (not a fixed ratio blend); common metformin talk is standard IR/XR clinical bands, not “X mg per mg rapa.” [community]
Metformin + acarbose + rapa “trio”: Forum longevity polypharmacy charts; animal synergy stories, human stack evidence thin. [community]
Senolytics on separate calendar: Dasatinib+quercetin (D+Q) or fisetin pulses timed away from weekly rapa day in some protocols (hit-and-run senolytic blocks vs continuous weekly rapa). [community]
Watch for
| Mouth sores and lab changes | Ulcers, fatigue, acne and constipation are reported, even at low amounts. Feeling fine can coexist with worse glucose or lipids. |
|---|---|
| Infection and healing | Label warnings include immunosuppression, delayed wound healing, lipid/blood-cell changes, lung inflammation and cancers. Clinical-use event rates do not quantify weekly longevity risk. |
| Exposure and reproductive risks | Grapefruit and strong CYP3A4/P-gp interactions can change exposure; forum booster arithmetic is unreliable. Label warnings also include fetal harm, fertility effects and breastfeeding risk. |
Notes
Mouth sores and feeling unwell are real reports. An adverse account describes ulcers at 1 mg weekly, then worse fatigue, acne and constipation after a higher dose. Its timeline and recap differ; low amounts did not prevent problems. Bad outcome from rapamycin (Personal report · Accessed 2026-09-30)
Feeling fine and favorable labs can diverge. A 5 mg weekly biohacker reported no felt side effects despite worse glucose/lipids, with diabetes, metformin and diet changes. Original monitoring talk includes fasting lipids, glucose/HbA1c, CBC, ApoB, hs-CRP and DEXA; those are not life-extension readouts. 6 month Rapamycin Results (Personal report · Accessed 2026-09-30)
Immunosuppression and delayed healing remain concerns. Pfizer warns about infections, wound healing, lipids, blood-cell changes, lung inflammation and cancers. Clinical-use frequencies do not quantify weekly longevity risk. Rapamune U.S. prescribing information (Official context · Accessed 2026-09-30)
Grapefruit and interacting drugs change exposure. Pfizer warns against grapefruit and strong CYP3A4/P-gp interactions. Forum “3–5×” booster arithmetic is not reliable personal dose conversion. Rapamune U.S. prescribing information (Official context · Accessed 2026-09-30)
Longevity hopes do not establish reproductive safety. The label warns of fetal harm, fertility effects and breastfeeding risk. Ovarian-aging enthusiasm or routine breaks cannot settle these concerns. Rapamune U.S. prescribing information (Official context · Accessed 2026-09-30)
Source context — Bad outcome from rapamycin: Long COVID account; narrative and TL;DR disagree on the number of 1 mg weeks. Drug causation and immune mechanism are not established.
Source context — 6 month Rapamycin Results: Author has type 2 diabetes, metformin co-use and diet/exercise changes. Linked lab image not inspected; calculator counterfactual is not measured rejuvenation.
Source context — Rapamune U.S. prescribing information: Approved clinical-use populations differ from healthy intermittent longevity users; labeled frequencies cannot be transferred. Preparation instructions not reproduced.
Full notes
Rapamycin, also called sirolimus, is a prescription mTOR inhibitor discussed for healthy aging. Community reports range from fewer aches and better stamina to no change, mouth sores or fatigue. Weekly experiments have not established human life extension.
What rapamycin is
- Sirolimus and rapamycin are the same drug. Rapamune is a brand. Longevity talk concerns swallowed tablets or compounded capsules. Oral solution, topical use and other rapalogs have separate contexts. Official context Community
- The idea is less growth signaling, more maintenance. mTOR helps cells respond to nutrients and grow. Forum users frame intermittent inhibition as encouraging cellular cleanup while allowing recovery between doses; that theory does not establish a rejuvenation result. Rapamycin Longevity News Official context
What people hope to gain
- Fewer aches and better recovery are reported. The feel thread includes energy and less stiffness, alongside tiredness or no change. Rapamycin Longevity News
- Fatigue communities report both improvement and setbacks. A September 2026 Long COVID account described better activity capacity after four months but substantial remaining symptoms. Other respondents reported uncertainty after 3.5 weeks or no neurological benefit. Reddit r/covidlonghaulers
- A longer healthy life remains the hope. Kauppi explicitly treats lifespan benefit as uncertain. Feeling younger or changing an age calculator cannot show that someone will live longer. Personal report Personal report
Doses people discuss
- 5–7 mg oral tablets once weekly is an established discussion band. The original generic-tablet record centers on 6 mg per administration, including a cited 2023 self-report survey. This describes off-label talk, not a validated longevity amount. Community
- Lower and higher weekly amounts remain separate. Original accounts include 2–3 mg and clinic-style 2–4 mg weekly beginnings, alongside separate 8–10 mg weekly reports. The recorded 3–10 mg range combines different users' amounts; it does not describe one person's progression. Community
- Longer intervals include 10–15 mg every other week. Older notes also contain every-10–14-day schedules. A fresh ME/CFS commenter reports 8 mg every 9 days, form unstated; another reports 12 mg compounded capsules every 14 days. These are per-dose totals. Community Personal report Personal report
- Daily and unusual pulses are minority patterns. Older notes include 1 mg every other day, 1–3 mg daily and teens–20+ mg intermittent outliers. A fatigue-thread user reports 1 mg daily for three weeks, then one week off, for autoimmune symptoms. Different purposes and exposure matter. Community Rapamycin Longevity News
Half-life: circulating claims and their origins
- About 60–63 hours is repeated label-derived shorthand. A fatigue-thread reply repeats 63 hours, without personal measurement. Original “10–14 days to clear” lore extrapolates half-lives rather than establishing an exact washout. Rapamycin Longevity News Community
- 6–8 hours and 83 hours are competing user calculations. Maxi estimates 6–8 hours after 14 mg oral use; cl-user challenges the model and cites an 83-hour fit after 8 mg tablets with berberine co-use. Neither establishes a population value. Rapamycin Longevity News
- Felt timing cannot measure blood elimination. The fatigue thread’s symptom-based 2.5-day guess is not measured kinetics. A weekly calendar cannot establish mTOR recovery either. Rapamycin Longevity News Community
When people notice a change
- Same-day sensations can be energy or tiredness. Both occur in the feel thread. Phoenix Rising’s Mary reports disrupted sleep after nighttime tablets; her corrected initial amount is 2 mg weekly. Rapamycin Longevity News Personal report
- Two weeks and several months are different reports. Presentlava reports less pain and better strength after week 2. RapAdmin recalls improved sleep after 3–6 months. Neither is a universal waiting period. Personal report Rapamycin Longevity News
- No noticeable benefit is also reported. Phil_Van_Treuren reports no effects at 8 mg weekly; another contributor has skin irritation without psychological benefit after a month. Rapamycin Longevity News
How long reported changes last
- Fatigue can last hours or into the next day. Arhu describes a few hours; scta123 reports afternoon-through-next-day tiredness after morning weekly use. Rapamycin Longevity News Rapamycin Longevity News
- About a day of euphoric fatigue appears in one account. DeStrider’s next-day report includes grapefruit, oil and other supplements; it cannot describe rapamycin alone. Rapamycin Longevity News
- Changes after stopping have no consistent time limit. Presentlava says first-course benefits persisted, without a duration. A separate adverse Long COVID account reports increased fatigue lasting about two months after stopping. Personal report Personal report
Long-term use, courses and pauses
- Weekly continuation and deliberate holidays both appear. Kauppi planned ongoing weekly use. Original clinic/forum lore discusses 4–8-week pauses every 3–6 months; a cycling thread repeats a competing 5-weeks-on/8-weeks-off claim. No superior calendar is demonstrated. Personal report Community Rapamycin Longevity News
- Some symptom-focused users describe six-week courses. Presentlava describes a second course planned for at least six weeks. That differs from indefinite longevity experimentation and gives no agreed off-period. Personal report
- Illness, ulcers and healing interrupt schedules. Kauppi records a one-week ulcer pause and travel/illness breaks. Older notes also describe pauses, lower amounts or longer intervals after lipid/glucose/CBC changes; surgical holds vary rather than following one universal deadline. Personal report Community Community
What deserves attention
- Mouth sores and feeling unwell are real reports. An adverse account describes ulcers at 1 mg weekly, then worse fatigue, acne and constipation after a higher dose. Its timeline and recap differ; low amounts did not prevent problems. Personal report
- Immunosuppression and delayed healing remain concerns. Pfizer warns about infections, wound healing, lipids, blood-cell changes, lung inflammation and cancers. Clinical-use frequencies do not quantify weekly longevity risk. Official context
- Grapefruit and interacting drugs change exposure. Pfizer warns against grapefruit and strong CYP3A4/P-gp interactions. Forum “3–5×” booster arithmetic is not reliable personal dose conversion. Official context Community
- Longevity hopes do not establish reproductive safety. The label warns of fetal harm, fertility effects and breastfeeding risk. Ovarian-aging enthusiasm or routine breaks cannot settle these concerns. Official context Community
Supporting research: different questions
- The label’s measured half-life is 62 ± 16 hours. Repeated-dose, stable renal-transplant blood elimination: not a measured healthy weekly-user clock. Official context
- PEARL did not significantly reduce visceral fat. Its 48-week trial used 5 or 10 mg compounded weekly. Women in the 10 mg arm showed lean-tissue and pain signals; some well-being measures improved at 5 mg. Similar adverse-event rates do not prove universal safety or lifespan extension. Official context
- 31.03% describes a product-specific blood-level comparison. The formulation study compared 24-hour concentrations per labeled milligram. It cannot convert every compounded capsule into a tablet dose or establish total exposure; products and people varied. Official context
Practical tradeoffs in community accounts
- Timing is shaped by sleep and training concerns. Original notes describe consistent weekdays and food context, morning/rest-day use and keeping hard lifting away from dose day. A marathon trainee reported poorer cardio performance and eye swelling 48 hours after dosing, resolving by day 4. Community Personal report
- Feeling fine and favorable labs can diverge. A 5 mg weekly biohacker reported no felt side effects despite worse glucose/lipids, with diabetes, metformin and diet changes. Original monitoring talk includes fasting lipids, glucose/HbA1c, CBC, ApoB, hs-CRP and DEXA; those are not life-extension readouts. Personal report Community
- Stacks make credit and blame harder to assign. Original discussion includes metformin/acarbose, NMN/NR, spermidine, separate fisetin or dasatinib–quercetin pulses, LDN and lipid/glucose medicines. These are separate agents, without a fixed rapamycin ratio; animal combo stories do not validate human stacks. Community
- There is no agreed longevity blood-level target. Older notes contrast peak versus pre-dose trough tests, optional absorption checks and transplant-driven monitoring. A proposed below-3 ng/mL trough is community framing, not an established longevity target. Community Community